RA Capital’s Strategic Buy‑Sell Play: Heavy Sells, Targeted Buy as Vor BioPharma Hits China Approvals and 9% Weekly Surge
RA Capital’s strategic Vor BioPharma buy signals confidence as telitacicept receives Chinese approvals—could spark price momentum.
4 minutes to read


